NDAINJECTIONINJECTABLE
Approved
Sep 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
4/8 — Partial
AMIDATE (etomidate) by Pfizer is clinical pharmacology etomidate is a general anesthetic without analgesic activity. First approved in 1982.
Drug data last refreshed 11h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AMIDATE (etomidate) is a rapid-acting intravenous general anesthetic without analgesic properties, used for induction and short-term maintenance of anesthesia in surgical and procedural settings. It produces anesthesia within one minute with a brief duration of 3–5 minutes at standard doses, offering rapid recovery comparable to or slightly faster than thiopental. Etomidate is characterized by minimal cardiovascular effects and hemodynamic stability, making it preferred in patients with compromised cardiac function.
LOE Approaching
As a mature product approaching loss of exclusivity, the brand team is likely focused on defending market share against generic competition and managing declining revenues.
Mechanism of Action
CLINICAL PHARMACOLOGY Etomidate is a general anesthetic without analgesic activity. Intravenous injection of etomidate produces anesthesia characterized by a rapid onset of action, usually within one minute. Duration of anesthesia is dose dependent but relatively brief, usually three to five…
Worked on AMIDATE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.